View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Dec. 31, 2016	Jan. 31, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Trading Symbol	SRDX
Entity Registrant Name	SURMODICS INC
Entity Central Index Key	0000924717
Current Fiscal Year End Date	--09-30
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		13,266,526

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Current Assets:
Cash and cash equivalents	$ 17,653	$ 24,987
Available-for-sale securities	27,474	21,954
Accounts receivable, net of allowance for doubtful accounts of $10 and $19 as of December 31, 2016 and September 30, 2016, respectively	6,504	6,869
Inventories	3,472	3,579
Income tax receivable	358	697
Prepaids and other	1,183	472
Total Current Assets	56,644	58,558
Property and equipment, net	20,186	19,601
Deferred tax assets	4,286	5,027
Intangible assets, net	21,094	22,525
Goodwill	25,694	26,555
Other assets	721	628
Total Assets	128,625	132,894
Current Liabilities:
Accounts payable	1,611	1,622
Accrued liabilities:
Compensation	1,364	5,418
Due to customers	340	881
Accrued other	1,563	1,109
Contingent consideration	925	925
Deferred revenue	131	180
Total Current Liabilities	5,934	10,135
Contingent consideration, less current portion	13,366	13,592
Deferred revenue, less current portion	258	188
Other long-term liabilities	1,884	2,146
Total Liabilities	21,442	26,061
Commitments and Contingencies (Note 15)
Stockholders’ Equity:
Series A Preferred stock- $.05 par value, 450,000 shares authorized; no shares issued and outstanding
Common stock- $.05 par value, 45,000,000 shares authorized; 13,268,530 and 13,208,443 shares issued and outstanding, respectively	663	660
Additional paid-in capital	7,009	6,754
Accumulated other comprehensive (loss) income	(935)	1,273
Retained earnings	100,446	98,146
Total Stockholders’ Equity	107,183	106,833
Total Liabilities and Stockholders’ Equity	$ 128,625	$ 132,894

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 10	$ 19
Series A Preferred stock, par value	$ 0.05	$ 0.05
Series A Preferred stock, shares authorized	450,000	450,000
Series A Preferred stock, shares issued	0	0
Series A Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	13,268,530	13,208,443
Common stock, shares outstanding	13,268,530	13,208,443

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Product sales	$ 7,701	$ 7,181
Royalties and license fees	8,001	7,954
Research, development and other	2,059	1,406
Total revenue	17,761	16,541
Operating costs and expenses:
Product costs	2,628	2,366
Research and development	5,970	3,634
Selling, general and administrative	4,862	3,648
Acquisition transaction, integration and other costs		2,491
Acquired intangible asset amortization	596	354
Contingent consideration accretion expense	437	109
Total operating costs and expenses	14,493	12,602
Operating income	3,268	3,939
Other income (loss):
Investment income, net	85	1
Foreign exchange gain (loss)	674	(135)
Other income (loss), net	759	(134)
Income before income taxes	4,027	3,805
Income tax provision	(1,727)	(1,152)
Net income	$ 2,300	$ 2,653
Basic net income per share	$ 0.17	$ 0.20
Diluted net income per share	$ 0.17	$ 0.20
Weighted average number of shares outstanding:
Basic	13,200	12,966
Diluted	13,446	13,186

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 2,300	$ 2,653
Other comprehensive (loss) income:
Unrealized holding gains (losses) on available-for-sale securities, net of tax	46	(2)
Foreign currency translation adjustments	(2,254)	408
Other comprehensive (loss) income	(2,208)	406
Comprehensive income	$ 92	$ 3,059

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Activities:
Net income	$ 2,300	$ 2,653
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,282	909
Stock-based compensation	789	684
Contingent consideration accretion	437	109
Unrealized foreign exchange (income) loss	(663)	135
Deferred taxes	742	753
Other	(5)	(3)
Change in operating assets and liabilities, net of acquisitions:
Accounts receivable	345	2,194
Inventories	73	(83)
Prepaids and other	(746)	(75)
Accounts payable and accrued liabilities	(2,713)	(1,354)
Income taxes	82	356
Deferred revenue	28
Net cash provided by operating activities	1,951	6,278
Investing Activities:
Purchases of property and equipment	(1,545)	(384)
Purchases of available-for-sale securities	(12,541)
Maturities of available-for-sale securities	7,071
Payments for acquisition, net of cash acquired		(18,166)
Net cash used in investing activities	(7,015)	(18,550)
Financing Activities:
Issuance of common stock	13	10
Payments for taxes related to net share settlement of equity awards	(2,129)	(353)
Payment of deferred financing costs	(38)
Payment of contingent consideration		(305)
Net cash used in financing activities	(2,154)	(648)
Effect of exchange rate changes on cash	(116)
Net change in cash and cash equivalents	(7,334)	(12,920)
Cash and Cash Equivalents:
Beginning of period	24,987	55,588
End of period	17,653	42,668
Supplemental Information:
Cash paid for income taxes	897	42
Noncash transactions from investing and financing activities:
Acquisition of property and equipment on account	227	54
Deferred financing costs in accounts payable	45
Issuance of performance shares, restricted and deferred stock units	$ 2,414	1,073
Creagh Medical Ltd [Member]
Operating Activities:
Net income		(300)
Noncash transactions from investing and financing activities:
Contingent consideration and debt assumed in Creagh Medical transaction		$ 9,857

Basis of Presentation	3 Months Ended
Basis of Presentation	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.”) (“GAAP”) and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, needed to fairly present the financial results of Surmodics, Inc. and subsidiaries (“Surmodics” or the “Company”) for the periods presented. These financial statements include some amounts that are based on management’s best estimates and judgments. These estimates may be adjusted as more information becomes available, and any adjustment could be significant. The impact of any change in estimates is included in the determination of net income in the period in which the change in estimate is identified. The results of operations for the three months ended December 31, 2016 are not necessarily indicative of the results that may be expected for the entire 2017 fiscal year. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2016, and footnotes thereto included in the Company’s Form 10-K as filed with the SEC on December 2, 2016.

New Accounting Pronouncements	3 Months Ended
New Accounting Pronouncements	Dec. 31, 2016
Accounting Policies [Abstract]
New Accounting Pronouncements	2. New Accounting Pronouncements Accounting Standards to be Implemented In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2014-09, Revenue from Contracts with Customers (ASC Topic 606). Principles of this guidance require entities to recognize revenue in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration an entity expects to be entitled to in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting standard will be effective for the Company beginning in the first quarter of fiscal year 2019 (October 1, 2018) using one of two prescribed retrospective methods. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s business model and consolidated results of operations, cash flows and financial position. The Company expects to complete its evaluation during fiscal 2017. Based on a preliminary assessment, the Company currently estimates the impact may be material due to the potential acceleration of minimum license fees and a one quarter acceleration of royalty revenue pursuant to our hydrophilic license agreements. In February 2016, the FASB issued Accounting Standards Update ASU 2016-02, Leases (ASC Topic 842). The new guidance primarily affects lessee accounting, while accounting by lessors will not be significantly impacted by the update. The update maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the statement of financial position for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning the first quarter of fiscal year 2020 (October 1, 2019) and will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses (ASC Topic 326), Measurement of Credit Losses on Financial Statements. This ASU requires a financial asset (or a group of financial assets) measured at an amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2020 (October 1, 2019). Early adoption is permitted and the guidance will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new guidance clarifies requirements for presentation and classification of the following items within the statement of cash flows: debt prepayments, settlement of zero coupon debt instruments, contingent consideration payments, insurance proceeds, securitization transactions and distributions from equity method investees. The update also addresses classification of transactions that have characteristics of more than one class of cash flows. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2018. Early adoption is permitted, including adoption in an interim period, and the guidance will be applied retrospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated statements of cash flows. In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The accounting standard will be effective for the Company beginning in its fiscal 2020. Early adoption is permitted, and the guidance will be applied prospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated financial statements. Accounting Standards Implemented In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting. The accounting standard intends to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The accounting standard is effective for the Company beginning in the first quarter of fiscal 2018 (October 1, 2017), and early adoption is permitted. The Company elected to early-adopt this accounting standard in the fourth quarter of fiscal 2016, for the fiscal year ended September 30, 2016. As a result of the adoption, the Company records excess tax benefits and certain tax deficiencies as income tax expense or benefit in the condensed consolidated statements of income, whereas such excess tax benefits or tax deficiencies were previously recorded in additional paid-in capital. As this guidance was applied retroactively to the beginning of the fiscal year ended September 30, 2016, previously reported quarterly income tax and net income for interim periods therein were adjusted for the effects of the adoption. This resulted in an adjustment to reduce the income tax provision and increase net income by $0.1 million in the three months ended December 31, 2015, with a corresponding increase in net income per basic and diluted share of $0.01 per share. The guidance also requires presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Prior to the adoption of ASU No. 2016-09, cash flows resulting from the tax benefits generated by tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) are classified as financing cash flows. During the three months ended December 31, 2015, the Company realized tax benefits from stock options resulting in approximately $0.1 million of gross excess tax benefits, which are included as a component of cash flows from operating activities for the three months ended December 31, 2015 in the accompanying condensed consolidated statements of cash flows. This amount was previously reported as a component of cash flows from financing activities, but has been reclassified to conform to current accounting guidance. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

+ Details

Business Combinations

3 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Business Combinations

3. Business Combinations

For all business combinations, the Company records all assets and liabilities of the acquired business, including goodwill and other identified intangible assets, at their respective fair values as of the acquisition date. Contingent consideration, if any, is recognized at its fair value on the acquisition date and changes in fair value are recognized in earnings until settlement. Acquisition-related transaction costs are expensed as incurred.

Creagh Medical Ltd.

On November 20, 2015, the Company acquired 100% of the outstanding common shares and voting shares of Creagh Medical Ltd. (“Creagh Medical”) located in Ballinasloe, Ireland. The acquisition was financed with cash on hand and contingent seller financing. The Company acquired Creagh Medical for up to €30 million (approximately $32 million as of the acquisition date), including an upfront payment of €18 million (approximately $19.3 million as of the acquisition date), and up to €12 million (approximately $12.8 million as of the acquisition date) based on achievement of revenue and value-creating operational milestones through September 30, 2018. The payment of the milestones, if any, will occur in the quarter ending December 31, 2018. Total transaction, integration and other costs associated with the Creagh Medical acquisition aggregated $2.4 million for the quarter ended December 31, 2015. The operating results of Creagh Medical have been included in the Company’s Medical Device segment since the acquisition date. The Company realized $0.5 million of revenue and a loss of $0.3 million from the Creagh Medical operations for the three months ended December 31, 2015.

Creagh Medical designs and manufactures high-quality percutaneous transluminal angioplasty (“PTA”) balloon catheters. Since 2006, Creagh Medical has grown its technical and product capability with PTA products approved throughout the world, including Europe, the United States, and Japan. With these resources, the Company is uniquely positioned to offer a total solutions approach from product design and development through in-house extrusion, balloon forming, top-assembly and packaging and regulatory capabilities to approved products for exclusive distribution.

The purchase price of Creagh Medical consisted of the following:

(Dollars in thousands)
Cash paid	$	18,449
Debt assumed		761
Contingent consideration		9,064
Total purchase price		28,274
Less cash and cash equivalents acquired		(251	)
Total purchase price, net of cash acquired	$	28,023

The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition:

	Fair Value (Dollars in thousands)			Estimated Useful Life (In years)
Current assets	$	896		N/A
Property and equipment		634		1.0-10.0
Trade name		75		N/A
Developed technology		1,787		7.0
In-process research and development		942		N/A
Customer relationships		11,119		7.0-10.0
Other noncurrent assets		81		N/A
Current liabilities		(942	)	N/A
Deferred tax liabilities		(9	)	N/A
Net assets acquired		14,583
Goodwill		13,440		N/A
Total purchase price, net of cash acquired	$	28,023

The Creagh Medical goodwill, which is a result of acquiring and retaining the Creagh Medical existing workforce and expected synergies from integrating their business into the Company’s Medical Device segment, is not deductible for tax purposes.

NorMedix, Inc.

On January 8, 2016, the Company acquired 100% of the shares of NorMedix, Inc. (“NorMedix”), a privately owned design and development company focused on ultra thin-walled, minimally invasive catheter technologies based in Plymouth, Minnesota. The acquisition was financed with cash on hand and contingent seller financing. The Company acquired NorMedix for up to $14.0 million, including an upfront payment of $7.0 million, and up to $7.0 million based on achievement of revenue and value-creating operational milestones through September 30, 2019. Contingent consideration associated with the NorMedix transaction is payable as earned. This acquisition strengthened the Company’s vascular device expertise and Research and Development (“R&D”) capabilities and was a significant component of the Company’s strategy to offer whole-product solutions to medical device customers, while continuing its commitment to consistently deliver innovation in coating technologies. Total transaction, integration and other costs associated with the NorMedix acquisition aggregated $0.1 million for the three months ended December 31, 2015. The operating results for NorMedix have been included in the Medical Device segment since the acquisition date.

The purchase price of NorMedix consisted of the following:

(Dollars in thousands)
Cash paid	$	6,905
Contingent consideration		3,520
Total purchase price		10,425
Less cash and cash equivalents acquired		(17	)
Total purchase price, net of cash acquired	$	10,408

The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition:

	Fair Value (Dollars in thousands)			Estimated Useful Life (In years)
Net current assets	$	113		N/A
Property and equipment		60		N/A
Developed technology		6,850		10.0-14.0
Customer relationships		900		4.0
Deferred tax asset		690		N/A
Other noncurrent asset		13		N/A
Accounts payable		(187	)	N/A
Deferred tax liabilities		(2,483	)	N/A
Net assets acquired		5,956
Goodwill		4,452		N/A
Total purchase price, net of cash acquired	$	10,408

The NorMedix goodwill is a result of acquiring and retaining the NorMedix existing workforce and expected synergies from integrating their business into the Medical Device segment. The goodwill is not deductible for tax purposes.

On a pro forma basis, as if the Creagh medical and NorMedix acquisitions had occurred as of the beginning of fiscal 2016, the Company’s consolidated revenues and net income would have been $17.6 million and $4.2 million for the three months ended December 31, 2015, with basic and diluted earnings per share of $0.32. This unaudited pro forma financial information includes adjustments for additional amortization expense on identifiable intangible assets of $0.4 million and contingent consideration accretion expense of $0.3 million, eliminating non-recurring transactional professional fees of $2.5 million, and tax effect impact of $0.3 million. The tax impact of the adjustments in all periods reflects no tax benefit from contingent consideration accretion as well as a significant portion of our transaction related costs in fiscal 2016 as they are not deductible for tax purposes. Further, Creagh Medical amortization expense does not reflect an Irish tax benefit as we acquired a net operating loss carryforward as of the acquisition date that was offset in the aggregate by deferred tax liabilities and valuation allowance. Therefore, the amortization of Creagh Medical intangible assets results in a decrease in deferred tax liabilities with a corresponding increase to a deferred tax valuation allowance. NorMedix amortization expense reflects a tax benefit based on our incremental U.S. tax rate.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Fair Value Measurements

3 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

The accounting guidance on fair value measurements defines fair value, establishes a framework for measuring fair value under GAAP, and expands disclosures about fair value measurements. The guidance is applicable for all financial assets and financial liabilities and for all nonfinancial assets and nonfinancial liabilities recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.

Fair Value Hierarchy

Accounting guidance on fair value measurements requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities.

The Company did not have any Level 1 assets as of December 31, 2016 and September 30, 2016.

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability.

The Company’s Level 2 assets as of December 31, 2016 and September 30, 2016 consisted of money market funds, commercial paper instruments and corporate bonds.

Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.

Level 3 liabilities at December 31, 2016 and September 30, 2016 consist of contingent consideration obligations for the achievement of revenue and value-creating milestones related to the acquisitions of Creagh Medical and NorMedix discussed in Note 3.

In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

In instances where the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of December 31, 2016
Assets
Cash equivalents	$	—	$	13,775	$	—		$	13,775
Available-for-sale securities		—		27,474		—			27,474
Total assets	$	—	$	41,249	$	—		$	41,249

Liabilities
Contingent consideration	$	—	$	—	$	(14,291	)	$	(14,291	)
Total liabilities	$	—	$	—	$	(14,291	)	$	(14,291	)

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of September 30, 2016
Assets
Cash equivalents	$	—	$	22,160	$	—		$	22,160
Available-for-sale securities		—		21,954				$	21,954
Total assets	$	—	$	44,114	$	—		$	44,114

Liabilities
Contingent consideration	$	—	$	—	$	(14,517	)	$	(14,517	)
Total liabilities	$	—	$	—	$	(14,517	)	$	(14,517	)

The following table summarizes the changes in the contingent consideration liabilities measured at fair value using Level 3 inputs for the three months ended December 31, 2016 and 2015:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Beginning balance	$	14,517		$	—
Additions		—			9,064
Fair value adjustments		—			—
Settlements		—			—
Interest accretion		437			109
Foreign currency translation (gain) loss		(663	)		135
Ending balance	$	14,291		$	9,308

There were no transfers of assets or liabilities to or from amounts measured using Level 3 fair value measurements during fiscal 2017 or 2016.

Valuation Techniques

The valuation techniques used to measure the fair value of assets are as follows:

Cash equivalents — These assets are classified as Level 2 and are carried at historical cost which is a reasonable estimate of fair value because of the relatively short time between origination of the instrument and its expected realization.

Available-for-sale securities — Fair market values for these assets are based on quoted vendor prices and broker pricing in active markets underlying the securities where all significant inputs are observable. To ensure the accuracy of quoted vendor prices and broker pricing, the Company performs regular reviews of investment returns to industry benchmarks and sample tests of individual securities to validate quoted vendor prices with other available market data.

Contingent consideration — The contingent consideration liabilities were determined based on discounted cash flow analyses that included revenue estimates, probability of strategic milestone achievement and a discount rate, which are considered significant unobservable inputs. For the revenue-based milestones, the Company discounted forecasted revenue by 14.1% to 22.8%, which represents the Company’s weighted average cost of capital for each transaction, adjusted for the short-term nature of the cash flows. The resulting present value of revenue was used as an input into an option pricing approach, which also considered the Company’s risk of non-payment of the revenue-based milestones. Non-revenue milestones were projected to have a 65-95% probability of achievement and related payments were discounted using the Company’s estimated cost of debt, or 5.6% to 6.7%. To the extent that actual results differ from these estimates, the fair value of the contingent consideration liabilities could change significantly. The contingent consideration liability related to the Creagh Medical acquisition is denominated in Euros and is not hedged. The Company recorded a foreign currency gain of $0.7 million and a loss of $0.1 million for the three months ended December 31, 2016 and 2015, respectively, related to this contingent consideration as this obligation was marked to period-end exchange rates.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Investments

3 Months Ended

Dec. 31, 2016

Investments Debt And Equity Securities [Abstract]

Investments

5. Investments

Investments consisted principally of commercial paper securities and are classified as available-for-sale as of December 31, 2016 and September 30, 2016. Available-for-sale securities are reported at fair value with unrealized gains and losses, net of tax, excluded from the condensed consolidated statements of income and reported in the condensed consolidated statements of comprehensive income as well as a separate component of stockholders’ equity in the condensed consolidated balance sheets, except for other-than-temporary impairments, which are reported as a charge to current earnings. A loss would be recognized when there is an other-than-temporary impairment in the fair value of any individual security classified as available-for-sale, with the associated net unrealized loss reclassified out of accumulated other comprehensive income with a corresponding adjustment to other income (loss). This adjustment results in a new cost basis for the investment. Interest earned on debt securities, including amortization of premiums and accretion of discounts, is included in other income. Realized gains and losses from the sales of debt securities, which are included in other income, are determined using the specific identification method.

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

	December 31, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	27,487	$	—	$	(13	)	$	27,474
Total	$	27,487	$	—	$	(13	)	$	27,474

	September 30, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	22,019	$	—	$	(65	)	$	21,954
Total	$	22,019	$	—	$	(65	)	$	21,954

The following table summarizes sales of available-for-sale debt securities:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016		2015
Proceeds from maturities	$	7,071	$	—
Gross realized gains	$	—	$	—
Gross realized losses	$	—	$	—

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Inventories

3 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Inventories

6. Inventories

Inventories are principally stated at the lower of cost or market using the specific identification method and include direct labor, materials and overhead, with cost of product sales determined on a first-in, first-out basis. Inventories consisted of the following components:

	December 31,		September 30,
(Dollars in thousands)	2016		2016
Raw materials	$	1,724	$	1,766
Work-in process		449		492
Finished products		1,299		1,321
Total	$	3,472	$	3,579

Other Assets

3 Months Ended

Dec. 31, 2016

Investments All Other Investments [Abstract]

Other Assets

7. Other Assets

Other assets consist of the following:

	December 31,		September 30,
(Dollars in thousands)	2016		2016
ViaCyte, Inc.	$	479	$	479
Other noncurrent assets		242		149
Other assets, net	$	721	$	628

The Company has invested a total of $5.3 million in ViaCyte, Inc. (“ViaCyte”), a privately-held California-based biotechnology firm that is developing a unique treatment for diabetes using coated islet cells, the cells that produce insulin in the human body. The balance of the investment of $0.5 million, which is net of previously recorded other-than-temporary impairments of $4.8 million is accounted for under the cost method and represents less than a 1% ownership interest. The Company does not exert significant influence over ViaCyte’s operating or financial activities.

The carrying value of each cost method investment is reviewed quarterly for changes in circumstances or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost method investments is not adjusted if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment.

Intangible Assets

3 Months Ended

Dec. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets

8. Intangible Assets

Intangible assets consist principally of acquired patents and technology, customer lists and relationships, licenses and trademarks. The Company recorded amortization expense of $0.6 million and $0.4 million for the three months ended December 31, 2016 and 2015, respectively.

Intangible assets consisted of the following:

	December 31, 2016
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	16,979	$	(6,434	)	$	10,545
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,610		(800	)		7,810
Non-compete		5.0		230		(69	)		161
Patents and other		16.5		2,322		(1,312	)		1,010
Subtotal				28,671		(9,145	)		19,526
Unamortized intangible assets:
In-process research and development				927		—			927
Trademarks and trade names				641		—			641
Total			$	30,239	$	(9,145	)	$	21,094

	September 30, 2016
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,692	$	(6,123	)	$	11,569
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,724		(618	)		8,106
Non-compete		5.0		230		(58	)		172
Patents and other		16.5		2,321		(1,275	)		1,046
Subtotal				29,497		(8,604	)		20,893
Unamortized intangible assets:
In-process research and development				987		—			987
Trademarks and trade names				645		—			645
Total			$	31,129	$	(8,604	)	$	22,525

Based on the intangible assets in service as of December 31, 2016, excluding any possible future amortization associated with acquired in-process research and development (“IPR&D”), which has not met technological feasibility as of December 31, 2016, estimated amortization expense for the remainder of fiscal 2017 and each of the next five fiscal years is as follows:

(Dollars in thousands)
Remainder of 2017	$	1,864
2018		2,439
2019		2,439
2020		2,264
2021		2,125
2022		2,085

Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, completion or abandonment of IPR&D intangible assets, changes in amortization periods, or other factors.

The Company defines IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and requires the IPR&D to be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or abandonment. Upon completion of the development project (generally when regulatory approval to market the product is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off.

Goodwill

3 Months Ended

Dec. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill

9. Goodwill

Goodwill represents the excess of the cost of an acquired entity over the fair value assigned to the assets purchased and liabilities assumed in connection with a business acquisition. Goodwill is not amortized but is subject, at a minimum, to annual tests for impairment in accordance with accounting guidance for goodwill. The carrying amount of goodwill is evaluated annually, and between annual evaluations if events occur or circumstances change indicating that the carrying amount of goodwill may be impaired.

Goodwill as of December 31, 2016 and September 30, 2016 totaled $25.7 million and $26.6 million, respectively. Goodwill in the Medical Device reporting unit represents the gross value from the acquisitions of Creagh Medical and NorMedix in fiscal 2016. Goodwill in the In Vitro Diagnostics reporting unit represents the gross value from the acquisition of BioFX Laboratories, Inc. (“BioFX”) in fiscal 2007.

Goodwill was not impaired in either reporting unit based on the outcome of the fiscal 2016 annual impairment test, and there have been no events or circumstances that have occurred in the first quarter of fiscal 2017 to indicate that goodwill has been impaired.

The change in the carrying amount of goodwill by segment for the three months ended December 31, 2016 was as follows:

(Dollars in thousands)	In Vitro Diagnostics		Medical Device			Total
Balance as of September 30, 2016	$	8,010	$	18,545		$	26,555
Translation adjustment		—		(861	)		(861	)
Balance as of December 31, 2016	$	8,010	$	17,684		$	25,694

Stock-based Compensation

3 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based Compensation

10. Stock-based Compensation

The Company has stock-based compensation plans under which it grants stock options, restricted stock awards, performance share awards, restricted stock units and deferred stock units. Accounting guidance requires all share-based payments to be recognized as an operating expense, based on their fair values, over the requisite service period.

The Company’s stock-based compensation expenses were allocated to the following expense categories:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016		2015
Product costs	$	13	$	6
Research and development		125		59
Selling, general and administrative		651		619
Total	$	789	$	684

As of December 31, 2016, approximately $6.2 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.5 years. The unrecognized compensation costs above include $2.6 million, remaining to be expensed over the life of the awards, based on payout levels associated with performance share awards that are currently anticipated to be fully expensed because the performance conditions are expected to exceed minimum threshold levels.

Stock Option Awards

The Company uses the Black-Scholes option pricing model to determine the weighted average grant date fair value of stock options granted. The weighted average per-share fair values of stock options granted during the three months ended December 31, 2016 and 2015 were $7.59 and $6.87, respectively. The assumptions used as inputs in the model were as follows:

	Three Months Ended
	December 31,
	2016			2015
Risk-free interest rates		1.7	%		2.0	%
Expected life (years)		4.6			4.6
Expected volatility		34.4	%		36.7	%
Dividend yield		0.0	%		0.0	%

The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award. The expected life of options granted was determined based on the Company’s experience. Expected volatility was based on the Company’s stock price movement over a period approximating the expected term. Based on management’s judgment, dividend yields were expected to be 0.0% for the expected life of the options. The Company also estimated forfeitures of options granted, which were based on historical experience.

Non-qualified stock options are granted at fair market value on the date of grant. Non-qualified stock options expire in seven to ten years or upon termination of employment or service as a Board member. With respect to members of our Board, non-qualified stock options generally become exercisable on a pro-rata basis within the one-year period following the date of grant. With respect to our employees, non-qualified stock options generally become exercisable with respect to 25% of the shares on each of the first four anniversaries following the grant date. The stock-based compensation table above includes stock option expenses recognized related to these awards, which totaled $0.3 million and $0.3 million during the three months ended December 31, 2016 and 2015, respectively.

The total pre-tax intrinsic value of options exercised during the three months ended December 31, 2016 and 2015 was less than $0.1 million in each period. The intrinsic value represents the difference between the average exercise price and the fair market value of the Company’s common stock on the last day of the respective fiscal period end.

Restricted Stock Awards

The Company has entered into restricted stock agreements with certain key employees, covering the issuance of common stock (“Restricted Stock”). Under accounting guidance, these shares are considered to be non-vested shares. The Restricted Stock is released to the key employees if they are employed by the Company at the end of the vesting period. Compensation expense has been recognized for the estimated fair value of the common shares and is being charged to income over the vesting term. The stock-based compensation expense table includes Restricted Stock expenses recognized related to these awards, which totaled $0.1 million in each of the three months ended December 31, 2016 and 2015, respectively.

Performance Share Awards

The Company has entered into performance share agreements with certain key employees and executives, covering the issuance of common stock (“Performance Shares”). Performance Shares vest upon the achievement of all or a portion of certain performance objectives (which may include financial or project objectives), which must be achieved during the performance period. The Organization and Compensation Committee of the Board of Directors (the “Committee”) approves the performance objectives used for our executive compensation programs, which objectives were cumulative revenue and cumulative earnings before interest, income taxes, depreciation and amortization (“EBITDA”) for the three-year performance periods for awards granted in fiscal 2015 (2015 – 2017), fiscal 2016 (2016 – 2018) and fiscal 2017 (2017 – 2019). Assuming that the minimum performance level is attained, the number of shares that may actually vest will vary based on performance from 20% (minimum) to 200% (maximum) of the target number of shares. Shares will be issued to participants as soon as practicable following the end of each performance period, subject to Committee approval and verification of results. Awards granted in fiscal 2014 were finalized in the three months ended December 31, 2016 and resulted in the issuance of 38,505 shares (maximum was 78,606 shares) based on the performance objectives relative to actual results achieved during the performance period. The per share compensation cost for each award is fixed on the grant date. Compensation expense is recognized in each period based on management’s best estimate of the achievement level of actual and forecasted results, as appropriate, compared with the specified performance objectives and the related impact on the number of Performance Shares expected to vest. The stock-based compensation expense table includes the Performance Shares expenses recognized related to these awards, which totaled $0.2 million for both the three months ended December 31, 2016 and 2015.

The fair values of the Performance Shares, at target, were $1.2 million, $1.3 million and $0.9 million in each fiscal year for awards granted in fiscal 2017, 2016 and 2015, respectively.

The aggregate number of shares that could be awarded to our executives if the minimum, target and maximum performance goals are met, based on the fair value at the date of grant is as follows:

Performance Period	Minimum Shares		Target Shares		Maximum Shares
Fiscal 2015 – 2017		8,440		42,199		84,398
Fiscal 2016 – 2018		13,268		66,338		132,676
Fiscal 2017 – 2019		10,437		52,185		104,370

1999 Employee Stock Purchase Plan

Under the 1999 Employee Stock Purchase Plan (“Stock Purchase Plan”), the Company is authorized to issue up to 600,000 shares of common stock. All full-time and part-time U.S. employees can choose to have up to 10% of their annual compensation withheld, with a limit of $25,000, to purchase the Company’s common stock at purchase prices defined within the provisions of the Stock Purchase Plan. As of December 31, 2016 and September 30, 2016, there was $0.1 million of employee contributions included in accrued liabilities in the condensed consolidated balance sheets. Stock compensation expense recognized related to the Stock Purchase Plan for the three months ended December 31, 2016 and 2015 totaled less than $0.1 million in each period. The stock-based compensation table includes the Stock Purchase Plan expenses.

Restricted Stock and Deferred Stock Units

During the three months ended December 31, 2016 and 2015, the Company awarded 6,570 and 8,916 restricted stock units (“RSUs”), respectively, under the 2009 Equity Incentive Plan to non-employee directors and certain key employees in foreign jurisdictions. Forfeiture of 74 RSUs occurred in the first quarter of fiscal 2017. As of December 31, 2016 and September 30, 2016, 35,378 and 32,101 RSUs were outstanding, respectively, with an estimated fair market value of $0.9 million for both periods. RSU awards are not considered issued or outstanding common stock of the Company until they vest. The estimated fair value of the RSUs was calculated based on the closing market price of Surmodics’ common stock on the date of grant. Compensation expense has been recognized for the estimated fair value of the common shares and is being charged to income over the vesting term. The stock-based compensation table includes RSU expenses recognized related to these awards, which totaled less than $0.1 million for both the three months ended December 31, 2016 and 2015.

Directors can also elect to receive their annual fees for services to the Board in deferred stock units (“DSUs”). Certain directors elected this option beginning on January 1, 2013 with deferral elections made annually. During the three months ended December 31, 2016 and 2015, 1,971 and 1,842 units, respectively, were issued with a total fair value of less than $0.1 million in each period. As of December 31, 2016 and September 30, 2016, outstanding DSUs totaled 23,048 and 21,077, respectively, with an estimated fair value of $0.6 million for both periods. These DSUs are fully vested. Stock-based compensation expense related to DSU awards, totaled less than $0.1 million for the three months ended December 31, 2016 and 2015, respectively.

Revolving Credit Facility	3 Months Ended
Revolving Credit Facility	Dec. 31, 2016
Text Block [Abstract]
Revolving Credit Facility	11. Revolving Credit Facility On November 2, 2016, the Company amended and restated the revolving credit facility. The new agreement increased the available principal to $30.0 million and extended the maturity of the previous facility by three years to November 2019. In addition, the agreement includes a $5.0 million multi-currency overdraft facility in Ireland. Borrowings under the credit facility, if any, will bear interest at a benchmark rate plus a margin ranging from 1.00% to 1.75% based on the Company’s leverage ratio, as defined in the loan agreement. A facility fee is payable quarterly on unused commitments at a rate of 0.15% per annum. The Company has the option to increase the credit facility in increments of $5.0 million up to an additional $20.0 million, subject to approval of the lender. The Company’s obligations under the credit facility are secured by substantially all of its assets, other than intellectual property and real estate, as well as the majority of its equity interest in its subsidiaries. In connection with the credit facility, the Company is required to comply with certain financial and non-financial covenants. As of December 31, 2016, the Company has no debt outstanding and was in compliance with all financial covenants.

Net Income Per Share Data

3 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Net Income Per Share Data

12. Net Income Per Share Data

Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options, non-vested stock relating to restricted stock awards, restricted stock units, deferred stock units and performance shares.

The following table sets forth the denominator for the computation of basic and diluted net income per share (in thousands):

	Three Months Ended
	December 31,
	2016		2015
Net income available to common shareholders	$	2,300	$	2,653
Basic weighted average shares outstanding		13,200		12,966
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares		246		220
Diluted weighted average shares outstanding		13,446		13,186

The calculation of weighted average diluted shares outstanding excludes outstanding stock options associated with the right to purchase 0.3 million and 0.4 million shares of common stock for the three months ended December 31, 2016 and 2015, respectively, as their inclusion would have had an antidilutive effect on diluted net income per share.

The Company’s Board of Directors has authorized the repurchase of up to $30.0 million of the Company’s outstanding common stock. This authorization does not have an expiration date.

Income Taxes	3 Months Ended
Income Taxes	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The Company recorded income tax provisions of $1.7 million and $1.2 million for the three months ended December 31, 2016 and 2015, respectively, representing effective tax rates of 42.9% and 30.3%, respectively. The Company’s effective tax reflects the impact of state income taxes, permanent tax items and discrete tax benefits. The effective income tax rate for the three month periods ended December 31, 2016 and 2015 differs from the U.S. federal statutory tax rate of 35.0% primarily due to transaction costs and contingent consideration accretion associated with the Creagh Medical and NorMedix acquisitions, the domestic production manufacturing deduction and the U.S. federal research and development income tax credit , operating losses in a jurisdiction where tax benefits are offset by a valuation allowance, and discrete tax expense related to expiring stock option awards. The total amount of unrecognized tax benefits, excluding interest and penalties that, if recognized, would affect the effective tax rate is $1.2 million as of both December 31, 2016 and September 30, 2016. Currently, the Company does not expect the liability for unrecognized tax benefits to change significantly in the next 12 months with the above balances classified on the condensed consolidated balance sheets in other long-term liabilities. Interest and penalties related to unrecognized tax benefits are recorded in income tax provision. The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. The Internal Revenue Service (“IRS”) completed an examination of the Company’s U.S. income tax return for fiscal 2012 in the fourth quarter of fiscal 2014 with a payment made associated with a timing adjustment. U.S. income tax returns for years prior to fiscal 2013 are no longer subject to examination by federal tax authorities. For tax returns for state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2006. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to 2011. Additionally, the Company has been indemnified of liability for any taxes relating to Creagh Medical and NorMedix for periods prior to the respective acquisition dates, pursuant to the terms of the related share purchase agreements. As of December 31, 2016 and September 30, 2016 there were no undistributed earnings in foreign subsidiaries.

Segment and Geographical Information

3 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment and Geographical Information

14. Segment and Geographical Information

The Company’s management evaluates performance and allocates resources based on reported results for two reportable segments, based on the criteria set forth in FASB ASC Topic 280, Segment Reporting, as follows: (1) the Medical Device unit, which is comprised of manufacturing balloons and catheters used for a variety of interventional cardiology, peripheral and other applications, surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, and neurovascular, and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic immunoassay as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings.

During fiscal 2016, the Company acquired Creagh Medical and NorMedix, which are included in the Medical Device segment subsequent to the respective acquisition dates, as further discussed in Note 3.

The tables below present segment revenue, operating income and depreciation and amortization, as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Revenue:
Medical Device	$	13,757		$	12,247
In Vitro Diagnostics		4,004			4,294
Total revenue	$	17,761		$	16,541

Operating income:
Medical Device	$	3,719		$	3,830
In Vitro Diagnostics		1,456			1,643
Total segment operating income		5,175			5,473
Corporate		(1,907	)		(1,534	)
Total operating income	$	3,268		$	3,939

Depreciation and amortization:
Medical Device	$	1,004		$	487
In Vitro Diagnostics		103			222
Corporate		175			200
Total depreciation and amortization	$	1,282		$	909

The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments.

Asset information by operating segment is not presented because the Company does not provide its chief operating decision maker assets by operating segment, as the data is not readily available or significant to the decision making process.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Litigation. From time to time, the Company has been, and may become, involved in various legal actions involving its operations, products and technologies, including intellectual property and employment disputes. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, which if granted, could require significant expenditures or result in lost revenue. The Company records a liability in the condensed consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. InnoCore Technologies BV. In March 2006, the Company entered into a license agreement whereby Surmodics obtained an exclusive license to a drug delivery coating for licensed products within the vascular field which included peripheral, coronary and neurovascular biodurable stent products. The license requires an annual minimum payment of 200,000 euros (equivalent to $211,000 using a euro to US dollar exchange rate of 1.0536 to the Euro as of December 31, 2016) until the last patent expires which is currently estimated to be September 2027. The total minimum future payments associated with this license are approximately $2.7 million. The license is currently utilized by one of the Company’s drug delivery customers.

New Accounting Pronouncements (Policies)	3 Months Ended
New Accounting Pronouncements (Policies)	Dec. 31, 2016
Accounting Policies [Abstract]
New Accounting Pronouncements	Accounting Standards to be Implemented In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2014-09, Revenue from Contracts with Customers (ASC Topic 606). Principles of this guidance require entities to recognize revenue in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration an entity expects to be entitled to in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting standard will be effective for the Company beginning in the first quarter of fiscal year 2019 (October 1, 2018) using one of two prescribed retrospective methods. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s business model and consolidated results of operations, cash flows and financial position. The Company expects to complete its evaluation during fiscal 2017. Based on a preliminary assessment, the Company currently estimates the impact may be material due to the potential acceleration of minimum license fees and a one quarter acceleration of royalty revenue pursuant to our hydrophilic license agreements. In February 2016, the FASB issued Accounting Standards Update ASU 2016-02, Leases (ASC Topic 842). The new guidance primarily affects lessee accounting, while accounting by lessors will not be significantly impacted by the update. The update maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the statement of financial position for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning the first quarter of fiscal year 2020 (October 1, 2019) and will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses (ASC Topic 326), Measurement of Credit Losses on Financial Statements. This ASU requires a financial asset (or a group of financial assets) measured at an amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2020 (October 1, 2019). Early adoption is permitted and the guidance will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new guidance clarifies requirements for presentation and classification of the following items within the statement of cash flows: debt prepayments, settlement of zero coupon debt instruments, contingent consideration payments, insurance proceeds, securitization transactions and distributions from equity method investees. The update also addresses classification of transactions that have characteristics of more than one class of cash flows. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2018. Early adoption is permitted, including adoption in an interim period, and the guidance will be applied retrospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated statements of cash flows. In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The accounting standard will be effective for the Company beginning in its fiscal 2020. Early adoption is permitted, and the guidance will be applied prospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated financial statements. Accounting Standards Implemented In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting. The accounting standard intends to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The accounting standard is effective for the Company beginning in the first quarter of fiscal 2018 (October 1, 2017), and early adoption is permitted. The Company elected to early-adopt this accounting standard in the fourth quarter of fiscal 2016, for the fiscal year ended September 30, 2016. As a result of the adoption, the Company records excess tax benefits and certain tax deficiencies as income tax expense or benefit in the condensed consolidated statements of income, whereas such excess tax benefits or tax deficiencies were previously recorded in additional paid-in capital. As this guidance was applied retroactively to the beginning of the fiscal year ended September 30, 2016, previously reported quarterly income tax and net income for interim periods therein were adjusted for the effects of the adoption. This resulted in an adjustment to reduce the income tax provision and increase net income by $0.1 million in the three months ended December 31, 2015, with a corresponding increase in net income per basic and diluted share of $0.01 per share. The guidance also requires presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Prior to the adoption of ASU No. 2016-09, cash flows resulting from the tax benefits generated by tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) are classified as financing cash flows. During the three months ended December 31, 2015, the Company realized tax benefits from stock options resulting in approximately $0.1 million of gross excess tax benefits, which are included as a component of cash flows from operating activities for the three months ended December 31, 2015 in the accompanying condensed consolidated statements of cash flows. This amount was previously reported as a component of cash flows from financing activities, but has been reclassified to conform to current accounting guidance. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

Business Combinations (Tables)

3 Months Ended

Dec. 31, 2016

Creagh Medical Ltd [Member]

Business Acquisition [Line Items]

Summary of Purchase Price

The purchase price of Creagh Medical consisted of the following:

(Dollars in thousands)
Cash paid	$	18,449
Debt assumed		761
Contingent consideration		9,064
Total purchase price		28,274
Less cash and cash equivalents acquired		(251	)
Total purchase price, net of cash acquired	$	28,023

Schedule of Purchase Price to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed

The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition:

	Fair Value (Dollars in thousands)			Estimated Useful Life (In years)
Current assets	$	896		N/A
Property and equipment		634		1.0-10.0
Trade name		75		N/A
Developed technology		1,787		7.0
In-process research and development		942		N/A
Customer relationships		11,119		7.0-10.0
Other noncurrent assets		81		N/A
Current liabilities		(942	)	N/A
Deferred tax liabilities		(9	)	N/A
Net assets acquired		14,583
Goodwill		13,440		N/A
Total purchase price, net of cash acquired	$	28,023

NorMedix, Inc. [Member]

Business Acquisition [Line Items]

Summary of Purchase Price

The purchase price of NorMedix consisted of the following:

(Dollars in thousands)
Cash paid	$	6,905
Contingent consideration		3,520
Total purchase price		10,425
Less cash and cash equivalents acquired		(17	)
Total purchase price, net of cash acquired	$	10,408

Schedule of Purchase Price to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed

The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition:

	Fair Value (Dollars in thousands)			Estimated Useful Life (In years)
Net current assets	$	113		N/A
Property and equipment		60		N/A
Developed technology		6,850		10.0-14.0
Customer relationships		900		4.0
Deferred tax asset		690		N/A
Other noncurrent asset		13		N/A
Accounts payable		(187	)	N/A
Deferred tax liabilities		(2,483	)	N/A
Net assets acquired		5,956
Goodwill		4,452		N/A
Total purchase price, net of cash acquired	$	10,408

Fair Value Measurements (Tables)

3 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of December 31, 2016
Assets
Cash equivalents	$	—	$	13,775	$	—		$	13,775
Available-for-sale securities		—		27,474		—			27,474
Total assets	$	—	$	41,249	$	—		$	41,249

Liabilities
Contingent consideration	$	—	$	—	$	(14,291	)	$	(14,291	)
Total liabilities	$	—	$	—	$	(14,291	)	$	(14,291	)

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of September 30, 2016
Assets
Cash equivalents	$	—	$	22,160	$	—		$	22,160
Available-for-sale securities		—		21,954				$	21,954
Total assets	$	—	$	44,114	$	—		$	44,114

Liabilities
Contingent consideration	$	—	$	—	$	(14,517	)	$	(14,517	)
Total liabilities	$	—	$	—	$	(14,517	)	$	(14,517	)

Schedule of Contingent Consideration Liabilities Measured at Fair Value

The following table summarizes the changes in the contingent consideration liabilities measured at fair value using Level 3 inputs for the three months ended December 31, 2016 and 2015:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Beginning balance	$	14,517		$	—
Additions		—			9,064
Fair value adjustments		—			—
Settlements		—			—
Interest accretion		437			109
Foreign currency translation (gain) loss		(663	)		135
Ending balance	$	14,291		$	9,308

Investments (Tables)

3 Months Ended

Dec. 31, 2016

Investments Debt And Equity Securities [Abstract]

Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

	December 31, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	27,487	$	—	$	(13	)	$	27,474
Total	$	27,487	$	—	$	(13	)	$	27,474

	September 30, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	22,019	$	—	$	(65	)	$	21,954
Total	$	22,019	$	—	$	(65	)	$	21,954

Sales of Available-for-Sale Debt Securities

The following table summarizes sales of available-for-sale debt securities:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016		2015
Proceeds from maturities	$	7,071	$	—
Gross realized gains	$	—	$	—
Gross realized losses	$	—	$	—

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Inventories (Tables)

3 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Components of Inventories

Inventories consisted of the following components:

	December 31,		September 30,
(Dollars in thousands)	2016		2016
Raw materials	$	1,724	$	1,766
Work-in process		449		492
Finished products		1,299		1,321
Total	$	3,472	$	3,579

Other Assets (Tables)

3 Months Ended

Dec. 31, 2016

Investments All Other Investments [Abstract]

Summary of Other Assets

Other assets consist of the following:

	December 31,		September 30,
(Dollars in thousands)	2016		2016
ViaCyte, Inc.	$	479	$	479
Other noncurrent assets		242		149
Other assets, net	$	721	$	628

Intangible Assets (Tables)

3 Months Ended

Dec. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following:

	December 31, 2016
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	16,979	$	(6,434	)	$	10,545
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,610		(800	)		7,810
Non-compete		5.0		230		(69	)		161
Patents and other		16.5		2,322		(1,312	)		1,010
Subtotal				28,671		(9,145	)		19,526
Unamortized intangible assets:
In-process research and development				927		—			927
Trademarks and trade names				641		—			641
Total			$	30,239	$	(9,145	)	$	21,094

	September 30, 2016
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,692	$	(6,123	)	$	11,569
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,724		(618	)		8,106
Non-compete		5.0		230		(58	)		172
Patents and other		16.5		2,321		(1,275	)		1,046
Subtotal				29,497		(8,604	)		20,893
Unamortized intangible assets:
In-process research and development				987		—			987
Trademarks and trade names				645		—			645
Total			$	31,129	$	(8,604	)	$	22,525

Estimated Amortization Expense

(Dollars in thousands)
Remainder of 2017	$	1,864
2018		2,439
2019		2,439
2020		2,264
2021		2,125
2022		2,085

Goodwill (Tables)

3 Months Ended

Dec. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule Of Carrying Amount Of Goodwill By Segment

The change in the carrying amount of goodwill by segment for the three months ended December 31, 2016 was as follows:

(Dollars in thousands)	In Vitro Diagnostics		Medical Device			Total
Balance as of September 30, 2016	$	8,010	$	18,545		$	26,555
Translation adjustment		—		(861	)		(861	)
Balance as of December 31, 2016	$	8,010	$	17,684		$	25,694

Stock-based Compensation (Tables)

3 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation Expenses

The Company’s stock-based compensation expenses were allocated to the following expense categories:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016		2015
Product costs	$	13	$	6
Research and development		125		59
Selling, general and administrative		651		619
Total	$	789	$	684

Assumptions Used in Stock Option Plans

The assumptions used as inputs in the model were as follows:

	Three Months Ended
	December 31,
	2016			2015
Risk-free interest rates		1.7	%		2.0	%
Expected life (years)		4.6			4.6
Expected volatility		34.4	%		36.7	%
Dividend yield		0.0	%		0.0	%

Schedule of Fair Value at the Date of Grant

The aggregate number of shares that could be awarded to our executives if the minimum, target and maximum performance goals are met, based on the fair value at the date of grant is as follows:

Performance Period	Minimum Shares		Target Shares		Maximum Shares
Fiscal 2015 – 2017		8,440		42,199		84,398
Fiscal 2016 – 2018		13,268		66,338		132,676
Fiscal 2017 – 2019		10,437		52,185		104,370

Net Income Per Share Data (Tables)

3 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Denominator for Computation of Basic and Diluted Net Income Per Share

The following table sets forth the denominator for the computation of basic and diluted net income per share (in thousands):

	Three Months Ended
	December 31,
	2016		2015
Net income available to common shareholders	$	2,300	$	2,653
Basic weighted average shares outstanding		13,200		12,966
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares		246		220
Diluted weighted average shares outstanding		13,446		13,186

Segment and Geographical Information (Tables)

3 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment Revenue, Operating Income and Depreciation and Amortization

The tables below present segment revenue, operating income and depreciation and amortization, as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Revenue:
Medical Device	$	13,757		$	12,247
In Vitro Diagnostics		4,004			4,294
Total revenue	$	17,761		$	16,541

Operating income:
Medical Device	$	3,719		$	3,830
In Vitro Diagnostics		1,456			1,643
Total segment operating income		5,175			5,473
Corporate		(1,907	)		(1,534	)
Total operating income	$	3,268		$	3,939

Depreciation and amortization:
Medical Device	$	1,004		$	487
In Vitro Diagnostics		103			222
Corporate		175			200
Total depreciation and amortization	$	1,282		$	909

New Accounting Pronouncements - Additional Information (Detail) - ASU 2016-09 [Member] $ / shares in Units, $ in Millions	3 Months Ended
	Dec. 31, 2015 USD ($) $ / shares
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Adjustment to reduce income tax provision	$ 0.1
Adjustment to increase net income	$ 0.1
Increase in net income per basic and diluted share \| $ / shares	$ 0.01
Excess tax benefit from stock-based compensation plans	$ 0.1

Business Combinations - Additional Information (Detail) $ / shares in Units, $ in Thousands, € in Millions				3 Months Ended
	Jan. 08, 2016 USD ($)	Nov. 20, 2015 USD ($)	Nov. 20, 2015 EUR (€)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) $ / shares	Nov. 20, 2015 EUR (€)
Business Acquisition [Line Items]
Acquisition transaction, integration and other costs					$ 2,491
Business acquisition, revenue recognized				$ 17,761	16,541
Business acquisition, loss recognized				2,300	2,653
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Outstanding common shares and voting shares percentage		100.00%				100.00%
Payments to acquire business				28,274
Upfront payments		$ 19,300	€ 18	18,449
Contingent milestone payments		12,800				€ 12
Acquisition transaction, integration and other costs					2,400
Business acquisition, revenue recognized					500
Business acquisition, loss recognized					(300)
Creagh Medical Ltd [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Payments to acquire business		$ 32,000	€ 30
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Outstanding common shares and voting shares percentage	100.00%
Payments to acquire business				10,425
Upfront payments	$ 7,000			$ 6,905
Contingent milestone payments	7,000
Acquisition transaction, integration and other costs					100
NorMedix, Inc. [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Payments to acquire business	$ 14,000
Creagh Medical and NorMedix [Member]
Business Acquisition [Line Items]
Consolidated pro forma revenue					17,600
Consolidated pro forma net income					$ 4,200
Basic and diluted earnings per share \| $ / shares					$ 0.32
Creagh Medical and NorMedix [Member] \| Unaudited Pro Forma [Member]
Business Acquisition [Line Items]
Amortization expense on intangible assets					$ 400
Contingent consideration accretion expense					300
Non-recurring professional fees					2,500
Tax effect impact					$ 300

Business Combinations - Summary of Purchase Price (Detail) $ in Thousands, € in Millions				3 Months Ended
	Jan. 08, 2016 USD ($)	Nov. 20, 2015 USD ($)	Nov. 20, 2015 EUR (€)	Dec. 31, 2016 USD ($)
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Cash Paid		$ 19,300	€ 18	$ 18,449
Debt assumed				761
Contingent consideration				9,064
Total purchase price				28,274
Less cash and cash equivalents acquired				(251)
Total purchase price, net of cash acquired				28,023
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Cash Paid	$ 7,000			6,905
Contingent consideration				3,520
Total purchase price				10,425
Less cash and cash equivalents acquired				(17)
Total purchase price, net of cash acquired				$ 10,408

Business Combinations - Summary of Purchase Price Allocation to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016
Business Acquisition [Line Items]
Goodwill	$ 25,694	$ 26,555
Developed Technology [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	11 years 9 months 18 days	11 years 9 months 18 days
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Current assets	$ 896
Property and equipment	634
Other noncurrent assets	81
Current liabilities	(942)
Deferred tax liabilities	(9)
Net assets acquired	14,583
Goodwill	13,440
Total purchase price, net of cash acquired	$ 28,023
Creagh Medical Ltd [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	1 year
Creagh Medical Ltd [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
Creagh Medical Ltd [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets	$ 1,787
Estimated Useful Life (In years)	7 years
Creagh Medical Ltd [Member] \| In-Process Research and Development [Member]
Business Acquisition [Line Items]
Intangible assets	$ 942
Creagh Medical Ltd [Member] \| Customer Relationship [Member]
Business Acquisition [Line Items]
Intangible assets	$ 11,119
Creagh Medical Ltd [Member] \| Customer Relationship [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	7 years
Creagh Medical Ltd [Member] \| Customer Relationship [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
Creagh Medical Ltd [Member] \| Trade Name [Member]
Business Acquisition [Line Items]
Intangible assets	$ 75
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Current assets	113
Property and equipment	60
Deferred tax asset	690
Other noncurrent assets	13
Accounts payable	(187)
Deferred tax liabilities	(2,483)
Net assets acquired	5,956
Goodwill	4,452
Total purchase price, net of cash acquired	10,408
NorMedix, Inc. [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets	$ 6,850
NorMedix, Inc. [Member] \| Developed Technology [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
NorMedix, Inc. [Member] \| Developed Technology [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	14 years
NorMedix, Inc. [Member] \| Customer Relationship [Member]
Business Acquisition [Line Items]
Intangible assets	$ 900
Estimated Useful Life (In years)	4 years

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Member] - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	$ 41,249	$ 44,114
Liabilities measured at fair value	(14,291)	(14,517)
Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	27,474	21,954
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	41,249	44,114
Significant Other Observable Inputs (Level 2) [Member] \| Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	27,474	21,954
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	(14,291)	(14,517)
Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	13,775	22,160
Cash equivalents [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	13,775	22,160
Contingent consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	(14,291)	(14,517)
Contingent consideration [Member] \| Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	$ (14,291)	$ (14,517)

Fair Value Measurements - Schedule of Contingent Consideration Liabilities Measured at Fair Value (Detail) - Contingent Consideration [Member] - Significant Unobservable Inputs (Level 3) [Member] - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 14,517
Additions		$ 9,064
Interest accretion	437	109
Foreign currency translation (gain) loss	(663)	135
Ending balance	$ 14,291	$ 9,308

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2017	Sep. 30, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfers in or out Level 3, Assets				$ 0
Transfers in or out Level 3, Liabilities				$ 0
Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of Probability Achievement of Contingent Consideration payment.	65.00%
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of Probability Achievement of Contingent Consideration payment.	95.00%
Contingent Consideration [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Foreign currency gain (loss)	$ 700,000	$ (100,000)
Contingent Consideration [Member] \| Minimum [Member] \| Non Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate	5.60%
Contingent Consideration [Member] \| Minimum [Member] \| Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate	14.10%
Contingent Consideration [Member] \| Maximum [Member] \| Non Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate	6.70%
Contingent Consideration [Member] \| Maximum [Member] \| Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate	22.80%
Scenario Forecast [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfers in or out Level 3, Assets			$ 0
Transfers in or out Level 3, Liabilities			$ 0

Investments - Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 27,487	$ 22,019
Unrealized Losses	(13)	(65)
Fair Value	27,474	21,954
Commercial paper and corporate bonds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	27,487	22,019
Unrealized Losses	(13)	(65)
Fair Value	$ 27,474	$ 21,954

Investments - Sales of Available-for-Sale Securities (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2016 USD ($)
Investments Debt And Equity Securities [Abstract]
Proceeds from maturities	$ 7,071

Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 1,724	$ 1,766
Work-in process	449	492
Finished products	1,299	1,321
Total	$ 3,472	$ 3,579

Other Assets - Summary of Other Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Schedule of Investments [Line Items]
Other assets, net	$ 721	$ 628
ViaCyte, Inc. [Member]
Schedule of Investments [Line Items]
Other assets, net	479	479
Other Noncurrent Assets [Member]
Schedule of Investments [Line Items]
Other assets, net	$ 242	$ 149

Other Assets - Additional Information (Detail) - ViaCyte, Inc. [Member] $ in Millions	3 Months Ended
	Dec. 31, 2016 USD ($)
Schedule of Investments [Line Items]
Equity method investment	$ 5.3
Other than temporary impairment loss on investment	4.8
Cost method of investment	$ 0.5
Maximum [Member]
Schedule of Investments [Line Items]
Company's ownership percentage	1.00%

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 0.6	$ 0.4

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016
Intangible Assets [Line Items]
Definite-lived intangible assets, Accumulated Amortization	$ (9,145)	$ (8,604)
Intangible assets, Gross Carrying Amount	30,239	31,129
Intangible assets, Net	$ 21,094	$ 22,525
Customer Lists and Relationships [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years 10 months 24 days	8 years 10 months 24 days
Definite-lived intangible assets, Gross Carrying Amount	$ 16,979	$ 17,692
Definite-lived intangible assets, Accumulated Amortization	(6,434)	(6,123)
Definite-lived intangible assets, Net	$ 10,545	$ 11,569
Core Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years	8 years
Definite-lived intangible assets, Gross Carrying Amount	$ 530	$ 530
Definite-lived intangible assets, Accumulated Amortization	$ (530)	$ (530)
Developed Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	11 years 9 months 18 days	11 years 9 months 18 days
Definite-lived intangible assets, Gross Carrying Amount	$ 8,610	$ 8,724
Definite-lived intangible assets, Accumulated Amortization	(800)	(618)
Definite-lived intangible assets, Net	$ 7,810	$ 8,106
Non-compete [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	5 years	5 years
Definite-lived intangible assets, Gross Carrying Amount	$ 230	$ 230
Definite-lived intangible assets, Accumulated Amortization	(69)	(58)
Definite-lived intangible assets, Net	$ 161	$ 172
Patents and Other [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	16 years 6 months	16 years 6 months
Definite-lived intangible assets, Gross Carrying Amount	$ 2,322	$ 2,321
Definite-lived intangible assets, Accumulated Amortization	(1,312)	(1,275)
Definite-lived intangible assets, Net	1,010	1,046
Definite-Lived Intangible Assets [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Gross Carrying Amount	28,671	29,497
Definite-lived intangible assets, Accumulated Amortization	(9,145)	(8,604)
Definite-lived intangible assets, Net	19,526	20,893
In-Process Research and Development [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	927	987
Trademarks and Trade Names [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	$ 641	$ 645

Intangible Assets - Estimated Amortization Expense (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2017	$ 1,864
2018	2,439
2019	2,439
2020	2,264
2021	2,125
2022	$ 2,085

Goodwill - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	$ 25,694	$ 26,555

Goodwill - Schedule Of Carrying Amount of Goodwill by Segment (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2016 USD ($)
Goodwill [Line Items]
Balance as of September 30, 2016	$ 26,555
Translation adjustment	(861)
Balance as of December 31, 2016	25,694
In Vitro Diagnostics [Member]
Goodwill [Line Items]
Balance as of September 30, 2016	8,010
Balance as of December 31, 2016	8,010
Medical Device [Member]
Goodwill [Line Items]
Balance as of September 30, 2016	18,545
Translation adjustment	(861)
Balance as of December 31, 2016	$ 17,684

Stock-based Compensation - Stock-based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 789	$ 684
Product costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	13	6
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	125	59
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 651	$ 619

Stock-based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Stock-Based Compensation Activity [Line Items]
Unrecognized compensation costs related to non-vested awards	$ 6,200,000
Weighted average period for recognition of compensation costs related to non-vested awards	2 years 6 months
Performance share awards fully expensed	$ 2,600,000
Weighted average per share fair value of stock options	$ 7.59	$ 6.87
Dividend yield	0.00%	0.00%
Vesting period				3 years	3 years
Stock compensation expenses recognized	$ 789,000	$ 684,000
Fiscal 2015 (2015 - 2017) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year	2015
Performance period end year	2017
Fiscal 2016 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year	2016
Performance period end year	2018
Fiscal 2017 (2017 - 2019) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year	2017
Performance period end year	2019
Scenario Forecast [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period			3 years
Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Total pre-tax intrinsic value of options exercised	$ 100,000	100,000
Performance Level [Member] \| Minimum [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage	20.00%
Performance Level [Member] \| Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Performance share awards, estimated vesting percentage	200.00%
Nonqualified Stock Options [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 300,000	300,000
Nonqualified Stock Options [Member] \| Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option exercisable on a pro-rata basis	1 year
Nonqualified Stock Options [Member] \| Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period	4 years
Nonqualified Stock Options [Member] \| Minimum [Member] \| Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service	7 years
Nonqualified Stock Options [Member] \| Maximum [Member] \| Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service	10 years
Nonqualified Stock Options [Member] \| Vesting Anniversary [Member] \| Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage	25.00%
Restricted Stock Awards
Stock-Based Compensation Activity [Line Items]
Restricted stock expense	$ 100,000	100,000
Performance Shares [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 200,000	200,000
Issuance of shares	38,505
Performance Shares [Member] \| Fiscal 2015 (2015 - 2017) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded					$ 900,000
Performance Shares [Member] \| Fiscal 2016 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded				$ 1,300,000
Performance Shares [Member] \| Scenario Forecast [Member] \| Fiscal 2017 (2017 - 2019) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded			$ 1,200,000
Performance Shares [Member] \| Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Issuance of shares	78,606
1999 Employee Stock Purchase Plan [Member]
Stock-Based Compensation Activity [Line Items]
Annual compensation withheld, maximum limit	$ 25,000
Employee contributions	100,000			$ 100,000
1999 Employee Stock Purchase Plan [Member] \| Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 100,000	$ 100,000
Common stock authorized, shares	600,000
Annual compensation withheld	10.00%
Restricted Stock Units (RSUs) [Member] \| 2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Number of stock units awarded	6,570	8,916
Number of stock units forfeited	74
Number of stock units outstanding	35,378			32,101
Number of stock units outstanding estimated fair value	$ 900,000			$ 900,000
Restricted Stock Units (RSUs) [Member] \| Maximum [Member] \| 2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 100,000	$ 100,000
Deferred Stock Units [Member] \| 2009 Equity Incentive Plan [Member] \| Director [Member]
Stock-Based Compensation Activity [Line Items]
Number of stock units awarded	1,971	1,842
Number of stock units outstanding	23,048			21,077
Number of stock units outstanding estimated fair value	$ 600,000			$ 600,000
Deferred Stock Units [Member] \| Maximum [Member] \| 2009 Equity Incentive Plan [Member] \| Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	100,000	$ 100,000
Number of stock units outstanding estimated fair value	$ 100,000	$ 100,000

Stock-based Compensation - Assumptions Used in Stock Option Plans (Detail)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rates	1.70%	2.00%
Expected life (years)	4 years 7 months 6 days	4 years 7 months 6 days
Expected volatility	34.40%	36.70%
Dividend yield	0.00%	0.00%

Stock-based Compensation - Schedule of Fair Value at the Date of Grant (Detail)	3 Months Ended
	Dec. 31, 2016 shares
Fiscal 2015 (2015 - 2017) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	8,440
Target Shares	42,199
Maximum Shares	84,398
Fiscal 2016 (2016 - 2018) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	13,268
Target Shares	66,338
Maximum Shares	132,676
Fiscal 2017 (2017 - 2019) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	10,437
Target Shares	52,185
Maximum Shares	104,370

Revolving Credit Facility - Additional Information (Detail) - Revolving Credit Facility [Member] - USD ($)		3 Months Ended
	Nov. 02, 2016	Dec. 31, 2016
Line Of Credit Facility [Line Items]
Revolving credit facility amount	$ 30,000,000
Line of credit facility, expiration period	3 years
Credit facility fee percentage	0.15%
Line of credit facility expiration month and year		2019-11
Debt outstanding		$ 0
Minimum [Member]
Line Of Credit Facility [Line Items]
Credit facility interest rate	1.00%
Maximum [Member]
Line Of Credit Facility [Line Items]
Credit facility interest rate	1.75%
Multi-currency Overdraft Facility [Member] \| Ireland
Line Of Credit Facility [Line Items]
Line of credit facility additional borrowing capacity	$ 5,000,000
Credit facility incremental of additional borrowings	5,000,000
Multi-currency Overdraft Facility [Member] \| Maximum [Member] \| Ireland
Line Of Credit Facility [Line Items]
Line of credit facility additional borrowing capacity	$ 20,000,000

Net Income Per Share Data - Denominator for Computation of Basic and Diluted Net Income Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Net income available to common shareholders	$ 2,300	$ 2,653
Basic weighted average shares outstanding	13,200	12,966
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares	246	220
Diluted weighted average shares outstanding	13,446	13,186

Net Income Per Share Data - Additional Information (Detail) - USD ($) shares in Millions	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Nov. 05, 2014
Earnings Loss Per Share [Line Items]
Weighted average diluted shares outstanding excluded outstanding stock options	0.3	0.4
Accelerated Share Repurchase Program [Member]
Earnings Loss Per Share [Line Items]
Maximum payments for repurchase of common stock			$ 30,000,000

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income tax provisions	$ 1,727,000	$ 1,152,000
Effective tax rates	42.90%	30.30%
U.S. federal statutory tax rate	35.00%	35.00%
Unrecognized tax benefits excluding interest and penalties that would impact effective tax rate	$ 1,200,000		$ 1,200,000
Undistributed earnings in foreign subsidiaries	$ 0		$ 0

Segment and Geographical Information - Additional Information (Detail)	3 Months Ended
	Dec. 31, 2016 Segment
Segment Reporting [Abstract]
Number of operating segments	2

Segment and Geographical Information - Segment Revenue, Operating Income and Depreciation and Amortization (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Revenue	$ 17,761	$ 16,541
Operating income	3,268	3,939
Depreciation and amortization	1,282	909
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income	5,175	5,473
Operating Segments [Member] \| Medical Device [Member]
Segment Reporting Information [Line Items]
Revenue	13,757	12,247
Operating income	3,719	3,830
Depreciation and amortization	1,004	487
Operating Segments [Member] \| In Vitro Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	4,004	4,294
Operating income	1,456	1,643
Depreciation and amortization	103	222
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income	(1,907)	(1,534)
Depreciation and amortization	$ 175	$ 200

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended
	Dec. 31, 2016 USD ($) € / $	Dec. 31, 2016 EUR (€)
Commitments And Contingencies [Line Items]
License agreement commencement date	2006-03	2006-03
Annual minimum payments for licenses	$ 211,000	€ 200,000
Exchange rate relating to license payment \| € / $	1.0536
Future minimum payments associated with license \| $	$ 2,700,000
Patents [Member]
Commitments And Contingencies [Line Items]
Patent expiry date	2027-09	2027-09